ArticleTranslational vision science & technology2025
Preclinical Study on the Long-Term Efficacy and Safety of Sustained-Release Gas6 Liposomes Combined With MERTK Gene Therapy for Retinitis Pigmentosa.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Our previous studies in Royal College of Surgeons (RCS) rats demonstrated that co-administration of MER proto-oncogene tyrosine kinase (MERTK) and its ligand Gas6 effectively protected photoreceptors and improved visual function. To facilitate clinical translation, we developed Gas6-loaded sustained-release liposomes (Gas6 Lips) using liposomes with superior biocompatibility and enhanced release stability as the delivery vehicle, and subsequently evaluated their long-term efficacy and safety in RCS rats and nonhuman primates. Methods: Gas6 Lips were synthesized using a thin-film hydration method and characterized for morphology, encapsulation efficiency, and release profile. A GMP-grade adeno-associated virus serotype 2 (AAV2)-BEST1-hMERTK vector was constructed. Experimental groups included the AAV-hMERTK group, the combination group with AAV-hMERTK and Gas6 Lips, and the control group. Therapeutic efficacy was assessed in RCS rats using electroretinography (ERG) and histological analysis. Long-term safety was evaluated in cynomolgus monkeys over 12 months. Results: Gas6 Lips had an average size of 144.1 nm and sustained Gas6 release for over 5 weeks. In RCS rats, the combination group exhibited significantly higher ERG b-wave amplitudes (52.116 ± 9.747 µV vs. 36.186 ± 7.156 µV, P < 0.01) and greater outer nuclear layer preservation (14.47 ± 1.43 µm vs. 10.41 ± 1.19 µm, P < 0.01) compared with the AAV-hMERTK group. These therapeutic effects persisted for over 7 weeks. In primates, no significant changes in retinal structure, ERG, or systemic immune responses were observed, with only transient and reversible mild ocular inflammation in the early post-treatment phase. Conclusions: Gas6 Lips combined with AAV2-BEST1-hMERTK effectively preserved retinal structure and function in RCS rats and demonstrated long-term safety in primates, supporting its potential for clinical translation. Translational Relevance: This can provide preclinical efficacy and safety data for the clinical translation of Gas6 Lips for the treatment of retinal pigmentosa (RP).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.